Skip to main content

CABA

Stock
Health Care
Biotechnology

Performance overview

CABA Price
Price Chart

Forward-looking statistics

Beta
1.48
Risk
100.00%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) has the potential to be applied across a broad range of autoimmune diseases.

Company info

SectorHealth Care
IndustryBiotechnology
Employees84
Market cap$508.8M

Fundamentals

Enterprise value-$25.9M
Revenue$0.0
Revenue per employee
Profit margin0.00%
Debt to equity23.69

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$2.54
Dividend per share
Revenue per share$0.00
Avg trading volume (30 day)$4M
Avg trading volume (10 day)$3M
Put-call ratio

Macro factor sensitivity

Growth-3.8
Credit+7.7
Liquidity+1.5
Inflation-4.1
Commodities-1.0
Interest Rates-5.8

Valuation

Dividend yield0.00%
PEG Ratio-0.68
Price to sales
P/E Ratio-0.68
Enterprise Value to Revenue
Price to book0.68

Upcoming events

Next earnings dayMay 15, 2025
Next dividend day
Ex. dividend day

News

Are Medical Stocks Lagging Cabaletta Bio (CABA) This Year?

Here is how Cabaletta Bio, Inc. (CABA) and KalVista Pharmaceuticals, Inc. (KALV) have performed compared to their sector so far this year.

Zacks Investment Research (October 9, 2023)
TipRanks reveals the top 10 health care sector analysts of the past decade

TipRanks' analyst ranking service ranks the top Wall Street firms of the past decade.

CNBC (May 21, 2023)
Cabaletta Bio's Updated Interim DSG3-CAART Data Fails To Cheer Investors

Cabaletta Bio Inc (NASDAQ: CABA) presented updated data from the DesCAARTes trial, evaluating DSG3-CAART in adults with mucosal-dominant pemphigus vulgaris (mPV), a blistering skin disease that affects mucous membranes. No dose-limiting toxicities were observed within three months.

Benzinga (May 18, 2022)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free